Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases -

Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
Information type: Other primary research
Source: British Medical Journal
Specialities: Cardiovascular system disorders | Endocrine system disorders | Obstetrics and gynaecology
Summary
Analysis (n=80 396 matched to 391,494 controls.) found most oral preparations were linked to increased VTE risks. Conjugated equine oestrogens with or without medroxyprogesterone acetate, were linked to highest risks. No increased risk was found for transdermal preparations.
UKMi comment

The researchers note their study show the vast majority of women using HRT continue to be prescribed oral preparations. They advise that in women with menopausal symptoms who already have an increased VTE risk because of comorbidities or obesity, they and their doctors should give greater consideration to transdermal HRT, in line with the NICE guideline.
Related links: NICE guidance